We investigated the use of 'prophylactic' donor lymphocyte infusions (DLI) containing 1 ؋ 10 7 CD3 ؉ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation (BMT), following conditioning with fludarabine 30 mg/m 2 /4 days and melphalan 70 mg/m 2 /2 days. GVHD prophylaxis consisted of cyclosporin A (CsA) 2 mg/kg daily with early tapering by day 60. Our goals were the rapid achievement of chimerism and disease control, providing an immunological platform for DLIs to treat refractory patients with hematological malignancies. Twelve heavily pre-treated patients with life expectancy less than 6 months were studied; none were in remission. Diagnoses were AML (n ‫؍‬ 4), MDS (n ‫؍‬ 1), ALL (n ‫؍‬ 3), CML (n ‫؍‬ 3) and multiple myeloma (n ‫؍‬ 1). Response rate was 75%. Three patients are alive at a median of 450 days (range, 450-540). Two patients are in remission of CML in blast crisis and AML for more than 14 months. Median survival is 116 days (range, 25-648). Six patients received 12 DLIs; three patients developed acute GVHD after the first infusion and were excluded from further DLIs, but no GVHD occurred among patients receiving subsequent DLIs. One patient with CML in blast crisis went into CR after the first DLI. The overall incidence of acute GVHD was 70%. Primary causes of death were infections (n ‫؍‬ 3), acute GVHD (n ‫؍‬ 3), chronic GVHD (n ‫؍‬ 1) and disease relapse (n ‫؍‬ 2). We observed high response and chimerism rates at the expense of an excessive incidence of GVHD. DLI given at day ؉30 post BMT caused GVHD in 50% of the patients, and its role in this setting remains unclear. The therapeutic benefit of allogeneic BMT is in part related to an immunological graft-versus-leukemia (GVL) effect that frequently evolves in the context of graft-versus-host disease (GVHD). The ability of donor lymphocytes to induce remission in patients relapsing after allogeneic transplantation illustrates the potency of this effect.
The therapeutic benefit of allogeneic BMT is in part related to an immunological graft-versus-leukemia (GVL) effect that frequently evolves in the context of graft-versus-host disease (GVHD). The ability of donor lymphocytes to induce remission in patients relapsing after allogeneic transplantation illustrates the potency of this effect. 1 Establishing donor-recipient tolerance with less toxic regimens may provide the basis for further immunological manipulations in order to maximize the GVL effect. However, rapidly evolving diseases may not be amenable to this strategy, considering that the immune-mediated elimination of malignant cells may take weeks or months to occur. This fact suggests the need for strategies to reinforce the immune-mediated phenomena in the post-transplant period.
Groups in Jerusalem and Houston pioneered the use of sub-lethal doses of fludarabine-based conditioning regimens. These regimens have been shown to be less toxic and to provide enough immunosuppression to prevent graft rejection and establish stable mixed or complete chimerism. 2, 3 The combination of melphalan and fludarabine has enabled allogeneic stem cell engraftment in the majority of patients treated, at least in the setting of HLA-identical transplantation. Patients with refractory relapses of advanced leukemias appear to benefit the least. 3 Mixed hematopoietic chimerism is the product of reciprocal graft-host tolerance. A rapidly achieved state of mutual tolerance may enable the use of donor lymphocytes in the post-transplant period, minimizing the development of GVHD. In order to separate GVL from GVHD, investigators have used lower doses of lymphocytes. 4 CsA is the most used drug for the prevention of GVHD. However, its inhibitory and modulatory actions may abrogate the GVL effect. Patients receiving CsA 5 mg/kg/day and methotrexate had a greater risk of relapse when compared to patients treated with CsA 1 mg/kg/day. 5 Furthermore, shortening the length of CsA taper post BMT has been associated with decreased risk of disease relapse in high-risk patients. 6 We postulated that by reducing the intensity of the conditioning regimen using fludarabine and melphalan ('mini BMT'), with CsA 2 mg/kg as GVHD prophylaxis with early tapering, it would be possible to achieve rapidly mixed or full chimerism with disease cytoreduction. This, in turn, would allow us to give prophylactic DLIs in a con-text of decreased burden of malignant cells. This strategy was designed to maximize the GVL effect against refractory and largely incurable, rapid evolving diseases.
Patients and methods

Eligibility criteria
Patients of any age were eligible for the study if they had hematological malignancies relapsing after allogeneic BMT, CML in blast crisis, or a medical condition that would preclude inclusion in 'standard' BMT protocols. Relapses post allogeneic BMT should not be responsive to DLI and have no acute or extensive chronic GVHD. Original BMT donors had to be willing to undergo G-CSF primed PBSC collection and all patients should have an HLA-identical sibling donor. The protocol was approved by the Institutional Review Board of the Instituto Nacional de Cancer. All donors and patients (or the persons legally responsible for them) signed written informed consent.
Patient characteristics
From March 1998 to August 1999, 12 patients with a life expectancy of less than 6 months were enrolled. Median age was 34 years (range, 8-53). Patients were divided into two groups: patients relapsing post allogeneic BMT (group 1, n ϭ 7) and patients without prior transplant (group 2, n ϭ 5).
Patients in group 1 had received and failed a median of 1 DLI (range, 1-4) at a median of 102 days prior to entry (range, 58-730). Median remission duration post first BMT was 147 days (range, 50-524) and median time between the two transplants was 338 days (range, 198-784) . Preparative regimens for the first BMT included busulfan and cyclophosphamide (n ϭ 5) and cyclophosphamide, vepeside and total body irradiation (n ϭ 2). Patient UPN 5 did not receive the second transplant due to fungal sepsis and Pneumocystis carinii pneumonia which developed after the second dose of fludarabine. Patient characteristics are summarized in Table 1 .
Preparative regimen and GVHD prophylaxis
The preparative regimen consisted of fludarabine 30 mg/m 2 i.v. on days Ϫ5 to Ϫ2 and melphalan 70 mg/m 2 i.v. on days Ϫ2 and Ϫ1. GVHD prophylaxis consisted of CsA administered at 2 mg/kg daily by continuous i.v. infusion from day Ϫ1. Doses were adjusted to maintain whole blood steady state levels at 100-200 ng/ml (initial six patients), and at 200-400 ng/ml (last six patients) by fluorescence polarization immunoassay (Cyclosporine Monoclonal Whole Blood, Abbott Laboratories, Chicago, IL, USA). By keeping the levels in the lower therapeutic range we intended to maximize the GVL effect; the target level was changed when severe acute GVHD occurred among the first six patients. CsA was to be tapered from day ϩ30, by approximately 30% per week, provided no GVHD was present. If a diagnosis of GVHD was made, the discontinuation schedule would follow the discretion of the attending physician. The protocol called for interruption of CsA on day ϩ60. Patients without evidence of GVHD by day ϩ30 received DLIs with 1 ϫ 10 7 CD3 ϩ cells/kg recipient body weight, on days ϩ30, ϩ60 and ϩ90. The presence of GVHD at any of these time points would exclude the patient from further DLIs.
Supportive care
All patients were treated in HEPA-filtered rooms. Highdose acyclovir was given for herpes viruses prophylaxis, and trimethoprim-sulfamethoxazole or pentamidine were used for Pneumocystis carinii prevention. All patients received prophylactic fluconazole. Immunohistochemical assays for cytomegalovirus pp65 antigenemia were performed weekly from engraftment. Patients developing any level of antigenemia received ganciclovir.
Donor characteristics, peripheral blood stem cells and donor lymphocyte collections
All recipient-donor pairs were HLA-matched siblings and all second transplants used the same donor. The preferred source of stem cells was the peripheral blood, but one donor refused G-CSF mobilization and donated bone marrow instead. All PBSC donors received G-CSF (Amgen, Thousand Oaks, CA, USA) 10 g/kg/day s.c. in two daily doses for 5 days. PBSC were collected on days 4 and 5 during a large volume leukapheresis using a COBE spectra apheresis system (Cobe Laboratories, Lakewood, CO, USA) or Haemonetics MCS plus (Haemonetics Corporation, Braintree, MA, USA). The target number of mononuclear cells was Ͼ5 ϫ 10 8 /kg recipient body weight and of CD34 ϩ cells was Ͼ3 ϫ 10 6 /kg. All PBSC products were infused fresh, unmanipulated, with the exception of PBSC donated to patient UPN 6, who received a frozen product due to donor logistic problems.
At post-transplant days ϩ30, ϩ60 and ϩ90 donors were to undergo leukapheresis. The percentage of CD3 ϩ cells in the product was determined using a fluorescein isothiocyanate-conjugated CD3-specific monoclonal antibody with a FACScan cell analyser (Becton Dickinson, San Jose, CA, USA). Bone marrow was collected following standard procedures.
Assessment of chimerism
Engraftment was confirmed by polymerase chain reaction amplification of variable number of tandem repeat (VNTR) loci (33.6, 33.1, 33.4, H-ras and pYNZ22). Chimerism was also assessed by cytogenetic analysis on unstimulated bone marrow, using conventional methods for sex mismatched donor-recipient pairs.
Study endpoints, definitions of response and statistical considerations
This was a pilot study designed to treat 20 patients. Primary study objectives were: (1) to achieve stable mixed or complete chimerism; (2) to determine remission rate; and (3) to assess the incidence of GVHD with this strategy. Should BMT ϭ blood and marrow transplantation; AML ϭ acute myelogenous leukemia; ALL ϭ acute lymphocytic leukemia; CML ϭ chronic myelogenous leukemia; MDS ϭ myelodysplastic syndrome; MM ϭ multiple myeloma; PS ϭ performance status; HTLV-I ϭ human T lymphotropic virus -I; HCV ϭ hepatitis virus C. Conditioning regimens: Cy/VP16/TBI ϭ cyclophosphamide, vepeside and total body irradiation; BuCy ϭ busulfan and cyclophosphamide. PS ϭ Zubrod performance status. severe acute GVHD occur in more than 50% of evaluable cases, the trial was to be interrupted. Neutrophil recovery was defined as the first of 3 consecutive days that the absolute neutrophil count exceeded 0.5 ϫ 10 9 /l and platelet recovery was defined as the first of 3 consecutive days that the platelet count exceeded 20 ϫ 10 9 /l, with platelet transfusion independence. CR was defined as Ͻ5% blasts in the bone marrow with a granulocyte count of Ͼ1.0 ϫ 10 9 /l and platelets Ͼ100 ϫ 10 9 /l with reconstitution of donor hematopoiesis as documented by cytogenetics or VNTR. Remission with partial hematologic recovery (HPR) was defined as above, except for platelets Ͻ100 ϫ 10 9 /l. Molecular remissions were not required for the definition of CR. Bone marrow aspirations for response and chimerism assessment were performed 3 to 4 weeks after transplant, monthly thereafter for 6 months and every 3 months afterwards.
We used the criteria of Bearman to grade regimen-related toxicity. 8 Infections were not scored as regimen-related toxicity. GVHD diagnosis required histological confirmation. Acute and chronic GVHD grading followed standard criteria. 9, 10 Cumulative actuarial probabilities of overall survival were calculated according to the Kaplan-Meier method.
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Results
Hematological response and survival
Five of nine evaluable patients (55%) achieved a complete response (CR) and two (20%) had a HPR. All patients had fast disappearance of peripheral blood blasts with the chemotherapy, including patient UPN 9, who had 95 ϫ 10 9 ALL blast cells/l at the start of fludarabine. None had evidence of peripheral blood leukemic cells by day ϩ7.
Bone Marrow Transplantation
Among the complete responders, two patients are currently in remission more than 14 months post treatment, two patients have relapsed (5 and 11 months post treatment) and one patient died in CR from chronic GVHD. Patient UPN 7 achieved a longer remission after mini-BMT than after the first transplant. Two patients died in HPR and two patients did not respond. Response could not be assessed in three patients. Three patients are alive at a median time of 450 days (range, 450-540) post transplant. Median survival is 116 days (range, 25-648). Figure 1 depicts the Kaplan-Meier survival curve for the group. Tables 2 and  3 summarize responses, remission duration and outcomes.
Chimerism
Group 1: Four patients achieved 100% bone marrow chimerism by day ϩ30; one of them has had stable complete Group 2: Two patients achieved 100% donor chimerism by day ϩ30; two patients converted to a predominantly donor pattern after the first DLI, with the development of grade II acute GVHD in both cases (patients UPN 10 and 8). The latter achieved 100% donor chimerism with hematological and molecular remission of CML in blast crisis.
Engraftment
The median number of infused CD34 ϩ cells per kg recipient body weight was 3.9 ϫ 10 6 (range, 1.25-7.84 ϫ 10 6 ). Median time to an absolute neutrophil count Ͼ0.5 ϫ 10 9 /l was 11 days (range, 10-23) (n ϭ 10), to platelet count Ͼ20 ϫ 10 9 /l was 14 days (range, 12-23) (n ϭ 9) and to platelet count Ͼ100 ϫ 10 9 /l was 31 days (range, 12-43) (n ϭ 6). Two patients in group 1 had graft rejection (patient UPN 6 rejected a previous transplant with ablative conditioning regimen).
GVHD and response
Three of five evaluable group 1 patients and four of five in group 2 developed acute GVHD. Acute GVHD developed in five of the seven responders (70%) and in three of five patients achieving a CR. Eight patients survived more than 100 days and five of them developed chronic GVHD (60%). Chronic GVHD was diagnosed in two of the three patients whose responses lasted longer than 6 months.
Three patients had unintended sub-therapeutic levels of CsA during the first month post BMT, and all developed acute GVHD. CsA dose reduction was done due to thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/ HUS) in two cases, and in one case was induced by drug interaction. The median time to CsA withdrawal in 6 cases was 52 days (range, 17-80).
Donor lymphocyte infusions
Six patients received 12 DLIs, with a median number of , respectively. Three patients (50%) developed acute GVHD after the first DLI, two of them while on therapeutic levels of CsA. Patient UPN 8 also developed pancytopenia. No acute GVHD developed among the three patients who completed treatment with DLI numbers 2 and 3. Three patients received the first infusion of donor lymphocytes in CR, two patients showed no response and patient UPN 10 recovered from transplant in accelerated phase CML that was converted to complete hematologic and molecular remission by the first DLI. Figure 2 depicts development of GVHD and DLIs.
Toxicity, infections and causes of death
Three patients developed grade II mucositis, and two patients had moderate veno-occlusive disease of the liver. The most serious toxicity in this heavily pretreated population, however, was severe TTP/HUS, observed in two cases. Patients UPN 2 and 3 responded to major reductions in CsA doses, but this led to the onset of acute GVHD in both cases (fatal in case UPN 3).
CMV reactivation occurred in eight of 10 subjects that engrafted, requiring prolonged and, in some cases, multiple Bone Marrow Transplantation courses of ganciclovir. Six of the eight patients had GVHD. However, no clinically apparent CMV disease occurred. Fungal sepsis was observed as a terminal event in two other cases and one patient developed pulmonary tuberculosis. One subject developed BM aplasia following the first DLI. Nine patients have died. Primary causes of death were infections (n ϭ 3), acute GVHD (n ϭ 3), chronic GVHD (n ϭ 1) and relapsed disease (n ϭ 2). Tables 2 and 3 summarize outcomes.
Considering both the high incidence and severity of GVHD the study was prematurely closed after 12 patients were enrolled.
Discussion
We studied a heterogeneous population that shared advanced stage of disease and refractoriness to first-line therapies. The combination of melphalan and fludarabine was well tolerated, even among this heavily pretreated group.
Peripheral blood was the preferable source of stem cells considering that, at least for CML, the relapse rate seems to be decreased when compared to bone marrow, and the velocity of hematological reconstitution with PBSC may be an advantage in this context. 12, 13 Disease status pre-transplant is a major determinant of response to therapy. In the MD Anderson Cancer Center experience, 86 patients treated with purine analog-containing, non-ablative regimens had a disease-free survival at 2 years of 23.3 Ϯ 5%, but the subgroup of non-refractory patients had a disease free survival of 46% at 2 years. 3 We observed an overall response rate of 75%, with 55% CRs. Three patients had responses lasting more than 6 months and two patients diagnosed with CML in blast crisis and AML are alive in unmaintained remission for more than 14 months.
Seven patients (70%) were complete chimeras by day ϩ30, but rapid achievement of mixed or complete chimerism, within the limitations of the method used to detect it, did not protect against GVHD. Seventy percent of the patients achieving complete chimerism developed GVHD, including three of five patients that were mixed chimeras pre-mini-BMT.
Spitzer and colleagues 14 treated 21 patients with cyclophosphamide 150-200 mg/kg, anti-thymocyte globulin (ATG) pre-and post transplant and thymic irradiation. CsA was used for GVHD prophylaxis. Ten patients received prophylactic DLIs 5 to 6 weeks post BMT. GVHD occurred in one of five patients who received one prophylactic DLI, and in three of four patients treated with more than one DLI.
All patients who developed GVHD post-prophylactic DLI in our trial did so after the first infusion. Three patients that went to the second infusion received the third, without signs of acute or chronic GVHD. It is possible that fludarabine and melphalan induced more cytokine release than the regimen studied by Spitzer et al, and for that reason, more GVHD occurred following the first infusion. There may also be a role for ATG and thymic irradiation in decreasing the rate of GVHD, as proposed by pre-clinical studies. 15, 16 The absence of GVHD post DLIs given at days ϩ60 and ϩ90 suggests that postponing the infusion until the damage induced by the conditioning is overcome, may minimize the risk of severe GVHD. 'Prophylactic' DLIs have been used after T cell-depleted marrow grafts, in patients receiving myeloablative cyclophosphamide and total body irradiation, and CsA given from day Ϫ4. The probability of acute GVHD grade II or greater was 100% in 12 recipients of 10 7 donor T cells/kg on day 30. However, patients receiving lymphocytes at 2 ϫ 10 6 cells/kg on day 30 and 5 ϫ 10 7 cells/kg on day 45 had a probability of acute GVHD of 31.5% (15.5% post T cell add-back). 17 We assumed that it would be possible to potentiate the GVL effect by minimizing the exposure to CsA and omitting methotrexate. This assumption was based on the expectation that GVHD incidence in the context of moderately ablative preparative regimens is lower. However, four of 10 evaluable patients developed acute GVHD prior to DLI, and another three after DLI, to a global incidence of 70%, mainly due to severe acute GVHD. This rate was deemed unacceptable and the study was interrupted. It is possible that the use of more effective GVHD prophylaxis could ultimately improve the results of our treatment strategy.
Future interventions may include the use of engineered clones of cytotoxic T lymphocytes that recognize hematopoietic tissue-restricted antigens or leukemia-restricted antigens, separating the anti-leukemia effect from GVHD. 18 In conclusion, we obtained a high response rate and achieved a state of mixed or complete hematopoietic chimerism among refractory patients at the expense of excessive incidence of GVHD. DLIs given on day ϩ30 after a non-myeloablative regimen caused GVHD in 50% of the patients, and their role in this setting remains unclear.
